Major abstracts in myeloma now, expertly moderated by Suzanne Lentzsch, MD, PhD! ASCO #ASCO24

Tremendous oral presentation from Michael May at ASCO with co-first author Margaux on the discrepancy between patients eligible for and patients who benefit from KRASi in NSCLC! Herbert Irving Comprehensive Cancer Center #ASCO24

Eight Columbia oncological physicians, scientists, and trainees have been awarded Conquer Cancer, the ASCO Foundation grants/awards to recognize and advance their impact on cancer research- Congratulations to these awardees, recognized at #ASCO24 !

Congratulations 👏 Dawn Hershman on her recent Irene and Arthur Fishberg Prize for her transformative contributions to #internalmedicine!

Greatly encouraging data -- linvoseltamab also cutting down on required hospitalization time for monitoring compared to tec! (And that's my mentor on stage!!) Suzanne Lentzsch, MD, PhD

SAVE THE DATE 🗓️ : Join experts from New York City's leading #amyloidosis centers on June 29 to learn more about new amyloidosis treatment options, #research 🧪 and active clinical trials. Open to patients, family members, caregivers, and medical personnel!

To a truly extraordinary peer mentor I've had the honor and pleasure of learning from -- we'll miss you!! Kristine Lacuna, MD Herbert Irving Comprehensive Cancer Center Michael May

Our multicenter study led by ⁦Danai Dima⁩ ⁦Michael Hughes⁩ on Venetoclax outcomes after Dara-failure in AL #Amyloidosis: VGPR rate ~90% Cardiac Organ RR~70% ~1 in 4 required another LoT at a median f/u of 22 mo. No treatment-related deaths! tandfonline.com/doi/full/10.10…

Linvoseltamab induced durable responses in patients with R/R myeloma, including those with high-risk features, according to updated data from the phase 1/2 LINKER-MM1 study. @slentzsch Herbert Irving Comprehensive Cancer Center NewYork-Presbyterian European Hematology Association #EHA2024 #mmsm onclive.com/view/linvoselt…

So excited to work alongside senior Journal of Clinical Oncology editorial fellow Alexandra Rojek under the one and only Suzanne Lentzsch, MD, PhD! Herbert Irving Comprehensive Cancer Center

Check out our paper on the clinical trial landscape in AL #Amyloidosis. Some interesting findings: - Just 25% industry-sponsored! - Most common primary endpoint: Hem RR and Safety - HRQoL measured in just ~1/3rd of trials (much room for improvement) cc Anita D'Souza - dFLC

Prevalence of MGUS in Africa:a Population-Based study by⁦⁦Herbert Irving Comprehensive Cancer Center⁩ team👉🏻our study suggests incidence of MGUS is similar between ethnicities👉🏻higher light-chain MGUS might reflect alternate etiologies, such as untreated HIV infection #mmsm academic.oup.com/jncics/advance…

Our analysis of intensive chemo (IC) in CBF-AML (200 pt) is out in eJHaem Journal! Kudos to lead author Alexandra Rojek We found: -similar EFS/OS betw IC + GO & IC alone -longer 3y EFS w/ IC + KIT inhibitor (85%) we eagerly await NCT02013648 results! onlinelibrary.wiley.com/doi/10.1002/jh…

📢Prof. Markus Mapara Markus Y. Mapara 🇺🇦 invites you to join us at the 9th COSTEM Congress in Berlin, Germany 🗓️24-27 Oct 2024 View our program⤵️ bit.ly/COSTEM-Program Arnon Nagler Nicolaus Kröger Nico Gagelmann

Many patients on BsAb therapy in #MultipleMyeloma discontinue Rx due to a severe toxicity (e.g. infection). But how long does remission hold once Rx stops? Could this hint whether fixed-duration BsAb therapy might offer lasting, treatment-free remission? Our multi-center study to

Organ Response and Progression Criteria for AL Amyloidosis. Morie Gertz Angela Dispenzieri Shaji Kumar Suzanne Lentzsch, MD, PhD Thanos Dimopoulos Vaishali Sanchorawala JAMA Oncology jamanetwork.com/journals/jamao…

Raj Chakraborty 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy ashpublications.org/blood/article-…